Overview

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative bioavailability of a single 300 mg dose of GBT440 administered as a high strength (1 × 300 mg) capsule versus a low strength (3 × 100 mg) capsule formulation in healthy fasted subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Global Blood Therapeutics